Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2011-004016-29 | EudraCT Number |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to characterize the safety, efficacy and dose response of BMS-945429 in subjects with active Psoriatic Arthritis and an inadequate response to Nonsteroidal anti-inflammatory drugs (NSAIDs) and non-biologic Disease modifying anti-rheumatic drugs (DMARDs).
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| PBO: Placebo matching BMS-945429 | Placebo Comparator |
| |
| BMS-945429 (25mg) | Experimental |
| |
| BMS-945429 (100mg) | Experimental |
| |
| BMS-945429 (200mg) | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Placebo matching BMS-945429 | Biological | Injection, Subcutaneous, 0 mg, every 4 weeks, Short term:24 weeks, Long term: After 24 Wk, selected dose, open-label |
|
| Measure | Description | Time Frame |
|---|---|---|
| Percent of Participants Achieving American College of Rheumatology Criteria 20% Response Rate (ACR20) | The ACR20/50/70 is a composite measure defined as both improvement of 20%, 50% or 70% in the number of tender and number of swollen joints, and a 20%, 50% or 70% improvement in three of the following five criteria: patient global assessment, physician global assessment, functional ability measure [most often Health Assessment Questionnaire (HAQ)], visual analog pain scale, and erythrocyte sedimentation rate or C-reactive protein (CRP). | At 16 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Percent of Participants Achieving Psoriasis Area Severity Index (PASI) 75 Response Rate | To calculate the PASI score, the psoriasis plaques found on each body region are graded for their combined redness, thickness, and scaliness. The severity of the plaques in each region is graded on a 0 to 4 scale, with 0 meaning no involvement and 4 meaning severe involvement. Next, the amount of surface area on each body region that is covered by the plaques is calculated. The total surface area affected by psoriasis is graded from 0 to 6, with 0 meaning no involvement and 6 meaning greater than 90 percent of the region covered in plaques. These grades are then fed into an equation to determine the patient's PASI score. The PASI score then is used as a clinical assessment of the patient's psoriasis involvement. A person free of psoriasis has a score of 0 and the score could be as high as 72. PASI 75 means that the person's PASI score dropped by 75 percent as a result of the psoriasis treatment. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Bristol-Myers Squibb | Bristol-Myers Squibb | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| San Diego Arthritis Medical Clinic | San Diego | California | 92108 | United States | ||
| Denver Arthritis Clinic |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 27059799 | Derived | Mease PJ, Gottlieb AB, Berman A, Drescher E, Xing J, Wong R, Banerjee S. The Efficacy and Safety of Clazakizumab, an Anti-Interleukin-6 Monoclonal Antibody, in a Phase IIb Study of Adults With Active Psoriatic Arthritis. Arthritis Rheumatol. 2016 Sep;68(9):2163-73. doi: 10.1002/art.39700. |
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Placebo | Subcutaneous, every 4 weeks for 24 weeks |
| FG001 | Clazakizumab (25mg) | Subcutaneous, 25 mg, every 4 weeks, for 24 weeks |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Period 1 |
|
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| BMS-945429 | Biological | Injection, Subcutaneous, 25 mg, every 4 weeks, Short term:24 weeks, Long term: After 24 Wk, selected dose, open-label |
|
| BMS-945429 | Biological | Injection, Subcutaneous, 100 mg, every 4 weeks, Short term:24 weeks, Long term: After 24 Wk, selected dose, open-label |
|
| BMS-945429 | Biological | Injection, Subcutaneous, 200 mg, every 4 weeks, Short term:24 weeks, Long term: After 24 Wk, selected dose, open-label |
|
| Week 16 and Week 24 |
| Percent of Participants Achieving ACR50 and ACR70 Response Rate | The ACR20/50/70 is a composite measure defined as both improvement of 20%, 50% or 70% in the number of tender and number of swollen joints, and a 20%, 50% or 70% improvement in three of the following five criteria: patient global assessment, physician global assessment, functional ability measure [most often Health Assessment Questionnaire (HAQ)], visual analog pain scale, and erythrocyte sedimentation rate or C-reactive protein (CRP). | Week 16 and Week 24 |
| Percent of Participants Achieving ACR20 Response Rate at Week 24 | The ACR20/50/70 is a composite measure defined as both improvement of 20%, 50% or 70% in the number of tender and number of swollen joints, and a 20%, 50% or 70% improvement in three of the following five criteria: patient global assessment, physician global assessment, functional ability measure [most often Health Assessment Questionnaire (HAQ)], visual analog pain scale, and erythrocyte sedimentation rate or C-reactive protein (CRP). | Week 24 |
| Percent of Participants Achieving a Health Assessment Questionnaire (HAQ) Response | For each item, there is a four-level difficulty scale that is scored from 0 to 3, representing normal (no difficulty) (0), some difficulty (1), much difficulty (2), and unable to do (3). There are 20 questions in eight categories of functioning - dressing, rising, eating, walking, hygiene, reach, grip, and usual activities. The highest component score in each category determines the score for the category, unless aids or devices are required. Dependence on equipment or physical assistance increases a lower score to the level of 2 to more accurately represent underlying disability. The eight category scores are averaged into an overall HAQ score on a scale from zero (no disability) to three (completely disabled). The scale is not truly continuous but has 25 possible values (i.e., 0, 0.125, 0.250, 0.375 … 3). Response is measured by a reduction of at least 0.3 unit from baseline in HAQ index. | Weeks 16 and Week 24 |
| Mean Change From Baseline at Week 16 in Short Form (36) [SF-36] Scores | The SF-36 questionnaire consists of eight scales yielding two summary measures: physical and mental health. The physical health measure includes four scales of physical functioning (10 items), role-physical (4 items), bodily pain (2 items), and general health (5 items). The mental health measure is composed of vitality (4 items), social functioning (2 items), role-emotional (3 items), and mental health (5 items). To score the SF-36, scales are standardized with a scoring algorithm to obtain a score ranging from 0 to 100. Higher scores indicate better health status. | Baseline and Week 16 |
| Mean Change From Baseline at Week 24 in SF-36 Scores | The SF-36 questionnaire consists of eight scales yielding two summary measures: physical and mental health. The physical health measure includes four scales of physical functioning (10 items), role-physical (4 items), bodily pain (2 items), and general health (5 items). The mental health measure is composed of vitality (4 items), social functioning (2 items), role-emotional (3 items), and mental health (5 items). To score the SF-36, scales are standardized with a scoring algorithm to obtain a score ranging from 0 to 100. Higher scores indicate better health status. | Baseline and Week 24 |
| Number of Participants With Anti-clazakizumab Antibodies | Up to 24 weeks |
| Denver |
| Colorado |
| 80230 |
| United States |
| New England Research Associates, Llc | Trumbull | Connecticut | 06611 | United States |
| Sarasota Arthritis Research Center | Sarasota | Florida | 34239 | United States |
| Arthritis Associates Of Mississippi | Jackson | Mississippi | 39202 | United States |
| Box Arthritis And Rheumatology Of The Carolinas, Pllc | Charlotte | North Carolina | 28210 | United States |
| Health Research Of Oklahoma | Oklahoma City | Oklahoma | 73103 | United States |
| East Penn Rheumatology Associates, P.C. | Bethlehem | Pennsylvania | 18015 | United States |
| Local Institution | Capital Federal | Buenos Aires | 1015 | Argentina |
| Local Institution | Capital Federal | Buenos Aires | 1425 | Argentina |
| Local Institution | Capital Federal | Buenos Aires | 1428 | Argentina |
| Local Institution | San Miguel de Tucumán | 4000 | Argentina |
| Local Institution | Cairns | Queensland | 4870 | Australia |
| Local Institution | Maroochydore | Queensland | 4558 | Australia |
| Local Institution | Woodville | South Australia | 5011 | Australia |
| Local Institution | Shenton Park | Western Australia | 6008 | Australia |
| Manitoba Clinic | Winnipeg | Manitoba | R3A 1M3 | Canada |
| Local Institution | Montreal | Quebec | H2L 1S6 | Canada |
| Centre De Rhumatologie De L Est Du Quebec | Rimouski | Quebec | G5L 8W1 | Canada |
| Centre De Recherche Musculo-Squelettique | Trois-Rivières | Quebec | G8Z 1Y2 | Canada |
| Local Institution | Pardubice | 530 02 | Czechia |
| Local Institution | Prague | 128 50 | Czechia |
| Local Institution | Bad Nauheim | 61231 | Germany |
| Local Institution | Erlangen | 91054 | Germany |
| Local Institution | Planegg | 82152 | Germany |
| Local Institution | Budapest | 1023 | Hungary |
| Local Institution | Budapest | 1062 | Hungary |
| Local Institution | Debrecen | 4012 | Hungary |
| Local Institution | Veszprém | 8200 | Hungary |
| Local Institution | Florence | 50139 | Italy |
| Local Institution | Naples | 80131 | Italy |
| Local Institution | México | Aguascalientes | 20127 | Mexico |
| Local Institution | Zapopan | Jalisco | 45190 | Mexico |
| Local Institution | Monterrey | Nuevo León | 64460 | Mexico |
| Local Institution | Bialystok | 15-351 | Poland |
| Local Institution | Dąbrówka | 62-069 | Poland |
| Local Institution | Elblag | 82-300 | Poland |
| Local Institution | Poznan | 60773 | Poland |
| Local Institution | Warsaw | 01-868 | Poland |
| Local Institution | Moscow | 115522 | Russia |
| Local Institution | Yaroslavl | 150003 | Russia |
| Local Institution | Pretoria | Gauteng | 0083 | South Africa |
| Local Institution | Pretoria | Gauteng | 0084 | South Africa |
| Local Institution | Durban | KwaZulu-Natal | 4001 | South Africa |
| Local Institution | Panorama, Cape Town | Western Cape | 7500 | South Africa |
| Local Institution | Pinelands, Cape Town | Western Cape | 7405 | South Africa |
| Local Institution | A Coruña | 15006 | Spain |
| Local Institution | Barcelona | 08036 | Spain |
| Local Institution | Seville | 41071 | Spain |
| FG002 | Clazakizumab (100mg) | Subcutaneous, 100 mg, every 4 weeks, for 24 weeks |
| FG003 | Clazakizumab (200mg) | Subcutaneous, 200 mg, every 4 weeks, for 24 weeks |
| COMPLETED |
|
| NOT COMPLETED |
|
|
| Period 2 |
|
|
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Placebo | Subcutaneous, every 4 weeks for 24 weeks |
| BG001 | Clazakizumab (25mg) | Subcutaneous, 25 mg, every 4 weeks, for 24 weeks |
| BG002 | Clazakizumab (100mg) | Subcutaneous, 100 mg, every 4 weeks, for 24 weeks |
| BG003 | Clazakizumab (200mg) | Subcutaneous, 200 mg, every 4 weeks, for 24 weeks |
| BG004 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants | Participants |
| ||||||||||||||||
| Age, Continuous | Mean | Standard Deviation | years |
| |||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Percent of Participants Achieving American College of Rheumatology Criteria 20% Response Rate (ACR20) | The ACR20/50/70 is a composite measure defined as both improvement of 20%, 50% or 70% in the number of tender and number of swollen joints, and a 20%, 50% or 70% improvement in three of the following five criteria: patient global assessment, physician global assessment, functional ability measure [most often Health Assessment Questionnaire (HAQ)], visual analog pain scale, and erythrocyte sedimentation rate or C-reactive protein (CRP). | Modified Intent-to-Treat (MITT) defined as all randomized subjects that received at least one dose of the study medication. | Posted | Number | percentage of participants | At 16 weeks |
|
|
| |||||||||||||||||||||||||||||||||||
| Secondary | Percent of Participants Achieving Psoriasis Area Severity Index (PASI) 75 Response Rate | To calculate the PASI score, the psoriasis plaques found on each body region are graded for their combined redness, thickness, and scaliness. The severity of the plaques in each region is graded on a 0 to 4 scale, with 0 meaning no involvement and 4 meaning severe involvement. Next, the amount of surface area on each body region that is covered by the plaques is calculated. The total surface area affected by psoriasis is graded from 0 to 6, with 0 meaning no involvement and 6 meaning greater than 90 percent of the region covered in plaques. These grades are then fed into an equation to determine the patient's PASI score. The PASI score then is used as a clinical assessment of the patient's psoriasis involvement. A person free of psoriasis has a score of 0 and the score could be as high as 72. PASI 75 means that the person's PASI score dropped by 75 percent as a result of the psoriasis treatment. | MITT | Posted | Number | percentage of participants | Week 16 and Week 24 |
| |||||||||||||||||||||||||||||||||||||
| Secondary | Percent of Participants Achieving ACR50 and ACR70 Response Rate | The ACR20/50/70 is a composite measure defined as both improvement of 20%, 50% or 70% in the number of tender and number of swollen joints, and a 20%, 50% or 70% improvement in three of the following five criteria: patient global assessment, physician global assessment, functional ability measure [most often Health Assessment Questionnaire (HAQ)], visual analog pain scale, and erythrocyte sedimentation rate or C-reactive protein (CRP). | MITT | Posted | Number | percentage of participants | Week 16 and Week 24 |
| |||||||||||||||||||||||||||||||||||||
| Secondary | Percent of Participants Achieving ACR20 Response Rate at Week 24 | The ACR20/50/70 is a composite measure defined as both improvement of 20%, 50% or 70% in the number of tender and number of swollen joints, and a 20%, 50% or 70% improvement in three of the following five criteria: patient global assessment, physician global assessment, functional ability measure [most often Health Assessment Questionnaire (HAQ)], visual analog pain scale, and erythrocyte sedimentation rate or C-reactive protein (CRP). | MITT | Posted | Number | percentage of participants | Week 24 |
| |||||||||||||||||||||||||||||||||||||
| Secondary | Percent of Participants Achieving a Health Assessment Questionnaire (HAQ) Response | For each item, there is a four-level difficulty scale that is scored from 0 to 3, representing normal (no difficulty) (0), some difficulty (1), much difficulty (2), and unable to do (3). There are 20 questions in eight categories of functioning - dressing, rising, eating, walking, hygiene, reach, grip, and usual activities. The highest component score in each category determines the score for the category, unless aids or devices are required. Dependence on equipment or physical assistance increases a lower score to the level of 2 to more accurately represent underlying disability. The eight category scores are averaged into an overall HAQ score on a scale from zero (no disability) to three (completely disabled). The scale is not truly continuous but has 25 possible values (i.e., 0, 0.125, 0.250, 0.375 … 3). Response is measured by a reduction of at least 0.3 unit from baseline in HAQ index. | MITT | Posted | Number | percentage of participants | Weeks 16 and Week 24 |
| |||||||||||||||||||||||||||||||||||||
| Secondary | Mean Change From Baseline at Week 16 in Short Form (36) [SF-36] Scores | The SF-36 questionnaire consists of eight scales yielding two summary measures: physical and mental health. The physical health measure includes four scales of physical functioning (10 items), role-physical (4 items), bodily pain (2 items), and general health (5 items). The mental health measure is composed of vitality (4 items), social functioning (2 items), role-emotional (3 items), and mental health (5 items). To score the SF-36, scales are standardized with a scoring algorithm to obtain a score ranging from 0 to 100. Higher scores indicate better health status. | MITT | Posted | Mean | Standard Error | score on a scale | Baseline and Week 16 |
| ||||||||||||||||||||||||||||||||||||
| Secondary | Mean Change From Baseline at Week 24 in SF-36 Scores | The SF-36 questionnaire consists of eight scales yielding two summary measures: physical and mental health. The physical health measure includes four scales of physical functioning (10 items), role-physical (4 items), bodily pain (2 items), and general health (5 items). The mental health measure is composed of vitality (4 items), social functioning (2 items), role-emotional (3 items), and mental health (5 items). To score the SF-36, scales are standardized with a scoring algorithm to obtain a score ranging from 0 to 100. Higher scores indicate better health status. | MITT | Posted | Mean | Standard Error | score on a scale | Baseline and Week 24 |
| ||||||||||||||||||||||||||||||||||||
| Secondary | Number of Participants With Anti-clazakizumab Antibodies | MITT | Posted | Number | participants | Up to 24 weeks |
|
|
Up to 24 weeks per participant
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Placebo | Subcutaneous, every 4 weeks for 24 weeks | 0 | 41 | 2 | 41 | 19 | 41 |
| EG001 | Clazakizumab (25mg) | Subcutaneous, 25 mg, every 4 weeks, for 24 weeks | 0 | 41 | 2 | 41 | 22 | 41 |
| EG002 | Clazakizumab (100mg) | Subcutaneous, 100 mg, every 4 weeks, for 24 weeks | 0 | 42 | 2 | 42 | 20 | 42 |
| EG003 | Clazakizumab (200mg) | Subcutaneous, 200 mg, every 4 weeks, for 24 weeks | 0 | 41 | 4 | 41 | 27 | 41 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Dystonia | Nervous system disorders | Systematic Assessment |
| ||
| Hemiparesis | Nervous system disorders | Systematic Assessment |
| ||
| Hypoaesthesia | Nervous system disorders | Systematic Assessment |
| ||
| Adute myocardial infarction | Cardiac disorders | Systematic Assessment |
| ||
| Bradycardia | Cardiac disorders | Systematic Assessment |
| ||
| Intervertebral disc disorder | Musculoskeletal and connective tissue disorders | Systematic Assessment |
| ||
| Muscular weakness | Musculoskeletal and connective tissue disorders | Systematic Assessment |
| ||
| Bladder neoplasm | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Systematic Assessment |
| ||
| Prostate cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Systematic Assessment |
| ||
| Transitional cell carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Systematic Assessment |
| ||
| Chest pain | General disorders | Systematic Assessment |
| ||
| Psoriasis | Skin and subcutaneous tissue disorders | Systematic Assessment |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Nasopharyngitis | Infections and infestations | Systematic Assessment |
| ||
| Pharyngitis | Infections and infestations | Systematic Assessment |
| ||
| Upper respiratory tract infection | Infections and infestations | Systematic Assessment |
| ||
| Urinary tract infection | Infections and infestations | Systematic Assessment |
| ||
| Bronchitis | Infections and infestations | Systematic Assessment |
| ||
| Alanine aminotransferase increased | Investigations | Systematic Assessment |
| ||
| Aspartate aminotransferase increased | Investigations | Systematic Assessment |
| ||
| Gamma-glutamyltransferase increased | Investigations | Systematic Assessment |
| ||
| Hypercholesterolaemia | Metabolism and nutrition disorders | Systematic Assessment |
| ||
| Hyperlipidaemia | Metabolism and nutrition disorders | Systematic Assessment |
| ||
| Diarrhoea | Gastrointestinal disorders | Systematic Assessment |
| ||
| Gastritis | Gastrointestinal disorders | Systematic Assessment |
| ||
| Nausea | Gastrointestinal disorders | Systematic Assessment |
| ||
| Injection site reaction | General disorders | Systematic Assessment |
| ||
| Injection site erythema | General disorders | Systematic Assessment |
| ||
| Headache | Nervous system disorders | Systematic Assessment |
| ||
| Migraine | Nervous system disorders | Systematic Assessment |
| ||
| Hypertension | Vascular disorders | Systematic Assessment |
|
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Study Director | CSL Behring | 610-878-4000 | clinicaltrials@cslbehring.com |
| ID | Term |
|---|---|
| D015535 | Arthritis, Psoriatic |
| ID | Term |
|---|---|
| D025242 | Spondylarthropathies |
| D025241 | Spondylarthritis |
| D013166 | Spondylitis |
| D013122 | Spinal Diseases |
| D001847 | Bone Diseases |
| D009140 | Musculoskeletal Diseases |
| D001168 | Arthritis |
| D007592 | Joint Diseases |
| D011565 | Psoriasis |
| D017444 | Skin Diseases, Papulosquamous |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C000604955 | clazakizumab |
Not provided
Not provided
Not provided
| Adverse Event |
|
| Withdrawal by Subject |
|
| Lost to Follow-up |
|
| Between 18 and 65 years |
|
| >=65 years |
|
| Male |
|
Subcutaneous, 100 mg, every 4 weeks, for 24 weeks |
| OG003 | Clazakizumab (200mg) | Subcutaneous, 200 mg, every 4 weeks, for 24 weeks |
|
|
|
|
|
|
Subcutaneous, 100 mg, every 4 weeks, for 24 weeks
| OG003 | Clazakizumab (200mg) | Subcutaneous, 200 mg, every 4 weeks, for 24 weeks |
|
|
Subcutaneous, 200 mg, every 4 weeks, for 24 weeks
|
|
Subcutaneous, 200 mg, every 4 weeks, for 24 weeks
|
|
|